| Name | Title | Contact Details |
|---|---|---|
Gerrick Rodrigues |
Director Of Information Technology | Profile |
BGI Americas Corporation is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kirin Pharma USA is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kurion creates technological solutions to minimize and stabilize nuclear and hazardous waste for safe, secure and permanent disposal. Kurion’s suite of waste separation, stabilization and robotic technologies are complemented by engineering and environmental services that together provide an execution platform to service the world’s largest nuclear and hazardous waste sites. Backed by venture capital firms Lux Capital, Firelake Capital and Acadia Woods Partners, the Kurion executive team employs a collective 150 years of industry experience managing nuclear and hazardous waste for commercial and government sites worldwide. Kurion is based in Irvine, Calif., and operates a technology development center at its radioactive materials licensed facility in Oak Ridge, Tenn.; a detritiation testing facility in Houston, Texas; two facilities in Richland, Wash., for non-radioactive demonstration testing, engineering and storage of mobile systems; and an office in Loveland, Colo. for engineering design and development.
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.
ALLERGY ASSOC is a Onalaska, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.